Polypharmazie – Interaktionen bei älteren Menschen

Zusammenfassung

Thrombozytenaggregationshemmer und Antikoagulanzien sind wichtige Standardmedikationen in der Prophylaxe und Therapie kardiovaskulärer Erkrankungen. Die oft multiple Medikation und durch zusätzliche Begleiterkrankungen notwendige weitere Medikation birgt besonders bei älteren Patienten ein hohes Risiko von Arzneimittelwechselwirkungen. Diese können das Blutungsrisiko oder im Fall des Wirkungsverlusts das Risiko thromboembolischer Ereignisse erhöhen. In diesem Artikel werden klinisch relevante Interaktionen von COX-Hemmern (COX: Cyclooxygenase) und Adenosinrezeptorantagonisten sowie von Vitamin-K-Antagonisten und direkten oralen Antikoagulanzien (DOAK) wie auch Strategien zur Vermeidung unerwünschter Wirkungen diskutiert.

Abstract

Platelet aggregation inhibitors and anticoagulants are important standard medications in the prophylaxis and therapy of cardiovascular diseases. The additional medication required to treat comorbidities bears the potential risk of drug interactions on pharmacokinetic and pharmacodynamic level, especially in elderly patients. This may increase the risk of bleeding or, in the event of loss of efficacy, the risk of thromboembolic events. This article outlines clinically relevant interactions of COX inhibitors and adenosine receptor antagonists as well as of vitamin K antagonists and DOAC. In addition, strategies to avoid adverse effects are discussed.

Was ist wichtig

Die im Alter zunehmende Prävalenz kardiovaskulärer wie auch weiterer Erkrankungen bedingt nahezu regelhaft die Notwendigkeit der Polypharmazie und damit ein höheres Potenzial unerwünschter Arzneimittelwirkungen. Die Kenntnis über Arzneimittelinteraktionen nimmt daher einen besonderen Stellenwert in der Behandlungsstrategie insbesondere älterer Patienten ein.

Schlüsselwörter

P-Glycoprotein - Blutungsereignis - Thromboembolie - Interaktionen - Arzneistoffmetabolismus

Keywords

drug metabolism - P-glycoprotein - bleeding events - thromboembolism - interactions

Publication History

Article published online:
05 December 2022

• Literatur

• 1 Budnitz DS, Shehab N, Lovegrove MC. et al. US Emergency Department Visits Attributed to Medication Harms, 2017–2019. JAMA 2021; 326: 1299-1309 DOI: 10.1001/jama.2021.13844. (PMID: 34609453)
• 2 Wester K, Jonsson AK, Spigset O. et al. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008; 65: 573-579 DOI: 10.1111/j.1365-2125.2007.03064.x. (PMID: 18070216)
• 3 FDA. Drug Development and Drug Interactions. Table of Substrates, Inhibitors and Inducers. Accessed September 29, 2022 at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
• 4 Mahady SE, Margolis KL, Chan A. et al. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut 2021; 70: 717-724 DOI: 10.1136/gutjnl-2020-321585. (PMID: 32747412)
• 5 Rahme E, Nedjar H, Bizzi A. et al. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. Aliment Pharmacol Ther 2007; 26: 1387-1398 DOI: 10.1111/j.1365-2036.2007.03523.x. (PMID: 17892525)
• 6 Catella-Lawson F, Reilly MP, Kapoor SC. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817 DOI: 10.1056/NEJMoa003199. (PMID: 11752357)
• 7 Polzin A, Dannenberg L, Helten C. et al. Excess Mortality in Aspirin and Dipyrone (Metamizole) Co-Medicated in Patients With Cardiovascular Disease: A Nationwide Study. J Am Heart Assoc 2021; 10: e022299 DOI: 10.1161/JAHA.121.022299. (PMID: 34726072)
• 8 Andrade C, Sandarsh S, Chethan KB. et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71: 1565-1575 DOI: 10.4088/JCP.09r05786blu. (PMID: 21190637)
• 9 Bykov K, Schneeweiss S, Donneyong MM. et al. Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors. Am J Cardiol 2017; 119: 651-657 DOI: 10.1016/j.amjcard.2016.10.052. (PMID: 27939386)
• 10 Lee CR, Luzum JA, Sangkuhl K. et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther 2022; DOI: 10.1002/cpt.2526.
• 11 Beitelshees AL, Thomas CD, Empey PE. et al. CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. J Am Heart Assoc 2022; 11: e024159 DOI: 10.1161/JAHA.121.024159. (PMID: 35156424)
• 12 Gessner A, Konig J, Fromm MF. Clinical Aspects of Transporter-Mediated Drug-Drug Interactions. Clin Pharmacol Ther 2019; 105: 1386-1394 DOI: 10.1002/cpt.1360. (PMID: 30648735)
• 13 Hartter S, Koenen-Bergmann M, Sharma A. et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 2012; 74: 490-500 DOI: 10.1111/j.1365-2125.2012.04218.x. (PMID: 22348256)
• 14 Chang SH, Chou IJ, Yeh YH. et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA 2017; 318: 1250-1259 DOI: 10.1001/jama.2017.13883. (PMID: 28973247)
• 15 Cascorbi I. Drug Interactions. In: Offermanns S, Rosenthal W. Encyclopedia of molecular Pharmacology. Cham: Springer; 2021. DOI: 10.1007/978-3-030-21573-6_53-16_53-1